Publications by authors named "Carl J Rosenthal"
Article Synopsis
- Allogeneic Vγ9Vδ2 T cells show promise for cancer therapy due to their safety and tumor-fighting abilities, but their clinical effectiveness has been limited by donor variability and other factors.
- Researchers are enhancing these T cells by selecting donors based on a biomarker (CD16), which improves their immune response and functionality, supported by RNA sequencing.
- Preclinical studies in ovarian cancer models confirm that these engineered CD16 Vδ2 T cells are effective, safe, and persist within the body, making them a potential new therapy for treating cancer.
Introduction: Fontan patients have variable exercise capacity. Contemporary understanding as to which factors predict high tolerance is limited.
Methods: Records from the Ahmanson/University of California, Los Angeles Adult Congenital Heart Disease Center were reviewed for adult Fontan patients who underwent CPET.
Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC-independent manner, making them ideal candidates for developing allogeneic, off-the-shelf cell-based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of γδ T cells have been explored.
View Article and Find Full Text PDF